OCUL
Ocular Therapeutix, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 70.61K | $537,539 | n/a | n/a |
| Q2 2026 | 90 | -7 | 115.87M | $1.14B | +4 | −12 |
| Q1 2026 | 101 | +4 | 114.41M | $983.07M | +11 | −8 |
| Q4 2025 | 96 | +1 | 115.21M | $1.40B | +2 | n/a |
| Q3 2025 | 18 | 0 | 82.57M | $965.26M | +1 | −1 |
| Q2 2025 | 15 | +1 | 57.50M | $533.65M | +1 | n/a |
| Q1 2025 | 11 | 0 | 20.34M | $149.08M | +1 | −1 |
| Q4 2024 | 11 | +1 | 19.58M | $167.25M | +2 | −1 |
| Q3 2024 | 9 | +1 | 15.07M | $131.15M | +1 | n/a |
| Q2 2024 | 8 | n/a | 16.30M | $111.49M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 4.05M | n/a | $27.73M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Adage Capital Partners ✦ | 3.70M | n/a | $25.27M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 3.45M | n/a | $23.62M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Point72 Asset Management ✦ | 2.71M | n/a | $18.51M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 1.11M | n/a | $7.60M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Two Sigma Investments ✦ | 536.12K | n/a | $3.67M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Marshall Wace ✦ | 429.59K | n/a | $2.94M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Wellington Management ✦ | 314.55K | n/a | $2.15M | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 266 holders, 206.22M shares, $1.70B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 11.98K sh · $87,363
Officer · 10.87K sh · $76,626
Officer · 9.99K sh · $70,430
Officer · 3.04K sh · $32,687
Officer · 3.30K sh · $35,531
Officer, Director · 21.65K sh · $233,160
Officer · 1.90K sh · $20,450
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology